Upfront Briefing
Neurology finally paid rent for Ionis, which landed FDA approval for Zanvastro nearly three weeks early and picked up a rare pediatric priority review voucher on the way out. Alexander disease affects about one in three million people, so nobody is modelling this as revenue — it is the first solo neurology launch, and a receipt for the antisense platform. AbbVie put up a 74% response rate and a 60% cut in progression-or-death risk for etentamig in myeloma. And GSK signed a $1.3B licensing pact with Hutchmed for a KRAS-EGFR conjugate that has not yet met a human being — $110M up front for a molecule whose Phase 1 starts later this year.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,747.7 |
1.1% |
13.0% |
| Nasdaq 100 |
29,482.3 |
1.2% |
17.0% |
| Russell 2000 |
2,968.3 |
0.5% |
18.3% |
| Healthcare (XLV) |
173.3 |
0.2% |
11.4% |
| Biotech (XBI) |
164.4 |
(0.6%) |
35.3% |
| Nasdaq Biotech (NBI) |
7,293.9 |
0.1% |
27.8% |
| Clinical Trials (BBC) |
53.4 |
(0.7%) |
41.9% |
|
- Biotech sat out the rally — XBI (0.6%) and BBC (0.7%) against the S&P 500's 1.1%, with XLV up 0.2% and NBI 0.1%. Equal-weighted XBI fell while cap-weighted NBI held green, putting the damage in SMID names on a session that repriced the Fed path lower — normally the setup they bid hardest. The money was in single names: Hutchmed rose 17% in London on the GSK licence.
- The broad tape had its best day since 4 August after Fed governor Christopher Waller said Thursday he could support holding the funds rate at 3.50–3.75% if disinflation continues, cutting rate-hike odds to roughly 50% from 63%. Equities ran ahead of the bond market on it: the 10-year finished at 4.756%, down only about 1.6bp, and VIX slipped to 14.20 with August nonfarm payrolls due Friday.
- Market data: U.S. cash close Thursday, 3 September 2026.
The Big 3
|
1
|
Ionis wins FDA approval for zanvastro in Alexander disease
|
- The FDA approved Zanvastro (zilganersen), an intrathecal antisense oligonucleotide dosed quarterly, for Alexander disease in pediatric and adult patients — 19 days ahead of its 22 September PDUFA date. In the 49-patient pivotal trial, gait speed on the 10-metre walk test stabilised at week 61 against a 33% decline in untreated controls. Ionis also received a rare pediatric disease priority review voucher.
- Why it matters: Ionis gets three things here, and only one of them is Alexander disease revenue. The label is US-only, since Recordati took ex-US rights in June, and AxD affects roughly one in three million people, so the P&L contribution is thin. The approval landed 19 days ahead of the 22 September PDUFA and carried a rare pediatric disease priority review voucher, which is a separately saleable asset. The real read is platform: a 49-patient trial showing gait-speed stabilisation against a 33% decline in controls got an intrathecal antisense drug across the line in a new CNS indication, which lifts the prior on Ionis' wholly owned neurology pipeline. Watch patient-finding, not volume.
- Source: STAT
- More: BioSpace
|
|
2
|
AbbVie posts Phase 3 win for etentamig in myeloma
|
- AbbVie's etentamig, a second-generation BCMA x CD3 bispecific T-cell engager, met both primary endpoints in the Phase 3 CERVINO trial in triple-class exposed relapsed/refractory myeloma: 74.0% objective response versus 45.7% for investigator's choice, and a 60% cut in progression-or-death risk (HR 0.40) across 393 patients with a median of three prior lines.
- Why it matters: The efficacy is good; the dosing schedule is the actual differentiator. Etentamig is a second-generation BCMA x CD3 engager going head-to-head with Tecvayli, Elrexfio and Lynozyfic, all of which carry step-up hospitalisation and frequent dosing. CERVINO ran monthly dosing after a single step-up dose with low CRS and low fatal-infection rates, which is what makes community and outpatient administration plausible. That is the commercial wedge in a crowded class, more than the 74% ORR against 45.7%. Full data hits an IMS plenary in Glasgow on 25 September, where the 12-month OS split of 87.9% versus 72.0% at 11.4 months' median follow-up is the number to test for maturity.
- Source: Endpoints
- More: Fierce Biotech
|
| 3 | GSK pays $110M up front for a Hutchmed asset that hasn't dosed a human |
- GSK licensed ex-Greater China rights to HMPL-A830, Hutchmed's first-in-class KRAS-EGFR antibody-targeted therapy conjugate, for $110M up front, up to $1.185B in milestones ($1.295B total) and tiered royalties, plus a right of first negotiation on a second ATTC. The asset is preclinical; Hutchmed leads a global Phase 1 (NCT07718581) starting in the second half of 2026. Hutchmed closed up 17%.
- Why it matters: $110M in cash for a molecule that has never been in a human is the number to sit with. HMPL-A830 does not start Phase 1 until the second half of this year, and Hutchmed runs that study. GSK is paying preclinical-stage money at clinical-stage prices for first call on a new conjugate class, a KRAS payload on an EGFR antibody rather than a cytotoxin, plus a right of first negotiation on a second ATTC. It follows Alteogen in January and the $1B Siran deal in June, so the Asia sourcing pattern is now a strategy. HCM rose 17%. The overhang is timing: this lands a day after FDA leaders promised harder looks at foreign trial sites.
- Source: Fierce Biotech
- More: BioSpace BioPharma Dive
|
Everything Else that broke
- Ivonescimab's final HARMONi-2 analysis showed a statistically significant overall survival win over Keytruda in first-line PD-L1-positive NSCLC in China — the fourth Phase 3 OS hit for the bispecific — though Akeso rose just 3.4% in Hong Kong as investors wait on ex-China replication. — Fierce Pharma
- The SEC and FDA signed a three-year information-sharing agreement, framed by both agencies as a signal to the market on insider trading around regulatory events. — Fierce Biotech
- ARPA-H will offer up to $125M to ease personalized RNA manufacturing bottlenecks. — BioSpace
- MFN carve-outs for orphan-only drugs are coming into focus, easing some rare-disease pricing overhang. — BioCentury
- FDA warned a Fresenius unit over a customer-complaint trend after a Form 483 and recall. — Fierce Pharma
- RevMed's Rasonque posted a 42% response rate and 16-month overall survival in supportive NSCLC data. — BioSpace
- TScan cut 75% of staff and pivoted its near-term focus to solid tumors. — BioSpace
- AbbVie completed its acquisition of Apogee Therapeutics and reaffirmed both full-year 2026 adjusted EPS guidance of $13.87-$14.07 and Q3 adjusted EPS guidance of $3.84-$3.88. — AbbVie 8-K
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
GSK licensed ex-Greater China rights to Hutchmed's KRAS-EGFR ATTC HMPL-A830 for $110M up front, up to $1.185B in milestones ($1.295B total) and tiered royalties. — BioPharma Dive
- Pfizer offloaded PF-08046031, a CD228 ADC it acquired in the $43B Seagen buyout and shelved earlier this year, to Medicus Pharma in a deal worth up to $1B+. — Fierce Biotech
VC / Private Financings
- Superluminal Medicines raised an oversubscribed $60M Series B led by BVF Partners, with new investors Deep Track Capital and Perceptive Advisors joining RA Capital, Insight Partners, NVIDIA and Eli Lilly, to take a selective biased MC4R agonist for rare genetic and hypothalamic obesity into Phase 1 by year-end. — Endpoints
IPOs / Follow-Ons
- Polyrizon announced a $4.0M registered direct offering and concurrent private placement with a single institutional investor, with closing expected on September 4. — GlobeNewswire
Academic Corner - Lentiviral in vivo CD19 CAR-T therapy showed manageable side effects and preliminary improvement across neurologic autoimmune disorders in 16 patients. — NEJM
- Nature Medicine reviewed how proximity-based therapies are expanding beyond the first approved PROTAC in breast cancer. — Nature Medicine
|
